This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mehra, N. Articles by Voest, E. E. Search for Related Content PubMed PubMed Citation Articles by Mehra, N. Articles by Voest, E. E.

Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases

Authors' Affiliations: ¹ Department of Medical Oncology and ² Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands; and ³ Primagen, Amsterdam, the Netherlands

Requests for reprints: Emile E. Voest, Department of Medical Oncology (F02.126), University Medical Center Utrecht, PO Box 85500, 3508 GA Utrecht, the Netherlands. Phone: 31-30-2506265; Fax: 31-30-2523741; E-mail: e.e.voest{at}umcutrecht.nl.

Purpose: We examined whether RNA expression of CD133, a surface molecule expressed on progenitors from hematopoietic and endothelial lineages, and CD146, a pan-endothelial marker, are increased in the blood of cancer patients and whether these factors correlate with patient characteristics and are predictive factors of survival.

Experimental Design: We developed a real-time quantification method (nuclear acid sequence-based amplification) to determine expression of CD146 and CD133 mRNA in the peripheral blood mononuclear cells of 131 progressive cancer patients, 37 healthy volunteers, and 5 patients who received granulocyte colony-stimulating factor. Overall survival and other clinicopathologic variables were obtained. Cox proportional hazards studies were done.

Results: We show that patients with metastatic disease have a significant increase in CD133 mRNA (P = 0.03), specifically patients with bone metastasis (P < 0.001). Cancer patients with high CD133 mRNA expression, using a defined cutoff value, show a decreased survival compared with patients with low or undetectable CD133 expression (21% versus 45% cumulative survival, respectively, after 20 months; P = 0.01). Among patients with metastasis to the bone, cumulative survival was 22%, compared with 61% for patients with high or low CD133 levels (P = 0.004). Multivariate analysis showed that CD133 expression is an independent predictor for overall survival in patients with bone metastases. CD146 mRNA was not increased in patients with cancer, nor did it correlate with clinical variables or survival.

Conclusion: CD133, but not CD146, mRNA expression is increased in cancer patients with metastatic disease, specifically with bone metastasis. In addition, CD133 mRNA expression seems to be an independent prognostic factor for overall survival.

This article has been cited by other articles:

				I. L. BOTCHKINA, R. A. ROWEHL, D. E. RIVADENEIRA, M. S. KARPEH JR., H. CRAWFORD, A. DUFOUR, J. JU, Y. WANG, Y. LEYFMAN, and G. I. BOTCHKINA Phenotypic Subpopulations of Metastatic Colon Cancer Stem Cells: Genomic Analysis Cancer Genomics Proteomics, January 1, 2009; 6(1): 19 - 29. [Abstract] [Full Text] [PDF]

				J. M. Rademaker-Lakhai, L. V. Beerepoot, N. Mehra, S. A. Radema, R. van Maanen, J. S. Vermaat, E. O. Witteveen, C. M. Visseren-Grul, L. Musib, N. Enas, et al. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C {beta}-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4474 - 4481. [Abstract] [Full Text] [PDF]

				N. Mehra, M. Penning, J. Maas, N. van Daal, R. H. Giles, and E. E. Voest Circulating Mitochondrial Nucleic Acids Have Prognostic Value for Survival in Patients with Advanced Prostate Cancer Clin. Cancer Res., January 15, 2007; 13(2): 421 - 426. [Abstract] [Full Text] [PDF]